{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T20:41:16Z","timestamp":1789764076714,"version":"4.0.1"},"reference-count":167,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,7]],"date-time":"2025-08-07T00:00:00Z","timestamp":1754524800000},"content-version":"vor","delay-in-days":371,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.ymthe.2024.06.020","type":"journal-article","created":{"date-parts":[[2024,6,18]],"date-time":"2024-06-18T02:53:22Z","timestamp":1718679202000},"page":"2489-2504","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Clinical perspectives: Treating spinal muscular atrophy"],"prefix":"10.1016","volume":"32","author":[{"given":"Molly A.","family":"McPheron","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8287-024X","authenticated-orcid":false,"given":"Marcia V.","family":"Felker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymthe.2024.06.020_bib1","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/0092-8674(95)90460-3","article-title":"Identification and characterization of a spinal muscular atrophy-determining gene","volume":"80","author":"Lefebvre","year":"1995","journal-title":"Cell"},{"key":"10.1016\/j.ymthe.2024.06.020_bib2","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1089\/hum.2022.189","article-title":"An overview of the therapeutic strategies for the treatment of spinal muscular atrophy","volume":"34","author":"Li","year":"2023","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2024.06.020_bib3","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1093\/hmg\/6.8.1205","article-title":"The survival motor neuron protein in spinal muscular atrophy","volume":"6","author":"Coovert","year":"1997","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.ymthe.2024.06.020_bib4","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1186\/s13023-017-0671-8","article-title":"Prevalence, incidence and carrier frequency of 5q- linked spinal muscular atrophy - a literature review","volume":"12","author":"Verhaart","year":"2017","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.ymthe.2024.06.020_bib5","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1177\/0883073807305788","article-title":"Consensus statement for standard of care in spinal muscular atrophy","volume":"22","author":"Wang","year":"2007","journal-title":"J.\u00a0Child Neurol."},{"key":"10.1016\/j.ymthe.2024.06.020_bib6","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/0960-8966(91)90052-T","article-title":"Workshop report: International SMA collaboration","volume":"1","author":"Munsat","year":"1991","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.ymthe.2024.06.020_bib7","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S1090-3798(99)80015-4","article-title":"Prenatal onset spinal muscular atrophy","volume":"3","author":"MacLeod","year":"1999","journal-title":"Eur. J. Paediatr. Neurol."},{"key":"10.1016\/j.ymthe.2024.06.020_bib8","doi-asserted-by":"crossref","first-page":"487","DOI":"10.3233\/JND-160177","article-title":"Type 0 spinal muscular atrophy: Further delineation of prenatal and postnatal features in 16 patients","volume":"3","author":"Grotto","year":"2016","journal-title":"J.\u00a0Neuromuscul. Dis."},{"key":"10.1016\/j.ymthe.2024.06.020_bib9","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1002\/ana.25549","article-title":"Severe brain involvement in 5q spinal muscular atrophy type 0","volume":"86","author":"Mendon\u00e7a","year":"2019","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.ymthe.2024.06.020_bib10","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1111\/pde.14538","article-title":"Skin necrosis in spinal muscular atrophy: Case report and review of the literature","volume":"38","author":"Weissman","year":"2021","journal-title":"Pediatr. Dermatol."},{"key":"10.1016\/j.ymthe.2024.06.020_bib11","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1097\/NEN.0000000000000144","article-title":"Spectrum of neuropathophysiology in spinal muscular atrophy type I","volume":"74","author":"Harding","year":"2015","journal-title":"J.\u00a0Neuropathol. Exp. Neurol."},{"key":"10.1016\/j.ymthe.2024.06.020_bib12","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.ajhg.2009.08.002","article-title":"A positive modifier of spinal muscular atrophy in the SMN2 gene","volume":"85","author":"Prior","year":"2009","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.ymthe.2024.06.020_bib13","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1038\/s41436-020-0754-0","article-title":"Spinal muscular atrophy diagnosis and carrier screening from genome sequencing data","volume":"22","author":"Chen","year":"2020","journal-title":"Genet. Med."},{"key":"10.1016\/j.ymthe.2024.06.020_bib14","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.gde.2013.03.003","article-title":"How genetic modifiers influence the phenotype of spinal muscular atrophy and suggest future therapeutic approaches","volume":"23","author":"Wirth","year":"2013","journal-title":"Curr. Opin. Genet. Dev."},{"key":"10.1016\/j.ymthe.2024.06.020_bib15","doi-asserted-by":"crossref","first-page":"6307","DOI":"10.1073\/pnas.96.11.6307","article-title":"A single nucleotide in the SMN gene regulates splicing and is responsible for spinal muscular atrophy","volume":"96","author":"Lorson","year":"1999","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2024.06.020_bib16","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1086\/338627","article-title":"Quantitative analyses of SMN1 and SMN2 based on real-time lightCycler PCR: Fast and highly reliable carrier testing and prediction of severity of spinal muscular atrophy","volume":"70","author":"Feldk\u00f6tter","year":"2002","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.ymthe.2024.06.020_bib17","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1177\/0883073807305668","article-title":"Spinal muscular atrophy diagnostics","volume":"22","author":"Prior","year":"2007","journal-title":"J.\u00a0Child Neurol."},{"key":"10.1016\/j.ymthe.2024.06.020_bib18","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1212\/WNL.0000000000000741","article-title":"Observational study of spinal muscular atrophy type I and implications for clinical trials","volume":"83","author":"Finkel","year":"2014","journal-title":"Neurology"},{"key":"10.1016\/j.ymthe.2024.06.020_bib19","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1097\/PEP.0b013e3182351f04","article-title":"Validation of the Children's Hospital of Philadelphia infant test of neuromuscular disorders (CHOP-INTEND)","volume":"23","author":"Glanzman","year":"2011","journal-title":"Pediatr. Phys. Ther."},{"key":"10.1016\/j.ymthe.2024.06.020_bib20","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1002\/ana.25101","article-title":"Natural history of infantile-onset spinal muscular atrophy","volume":"82","author":"Kolb","year":"2017","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.ymthe.2024.06.020_bib21","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1212\/WNL.0000000000002445","article-title":"Results from a phase 1 study of nusinersen (ISIS-SMN(Rx)) in children with spinal muscular atrophy","volume":"86","author":"Chiriboga","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.ymthe.2024.06.020_bib22","doi-asserted-by":"crossref","first-page":"3017","DOI":"10.1016\/S0140-6736(16)31408-8","article-title":"Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study","volume":"388","author":"Finkel","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.ymthe.2024.06.020_bib23","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa1702752","article-title":"Nusinersen versus sham control in infantile-onset spinal muscular atrophy","volume":"377","author":"Finkel","year":"2017","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2024.06.020_bib24","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1056\/NEJMoa1710504","article-title":"Nusinersen versus sham control in later-onset spinal muscular atrophy","volume":"378","author":"Mercuri","year":"2018","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2024.06.020_bib25","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/j.nmd.2019.09.007","article-title":"Nusinersen initiated in infants during the presymptomatic stage of spinal muscular atrophy: Interim efficacy and safety results from the phase 2 NURTURE study","volume":"29","author":"De Vivo","year":"2019","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.ymthe.2024.06.020_bib26","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1002\/mus.27853","article-title":"Continued benefit of nusinersen initiated in the presymptomatic stage of spinal muscular atrophy: 5-year update of the NURTURE study","volume":"68","author":"Crawford","year":"2023","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.ymthe.2024.06.020_bib27","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S2352-4642(22)00342-X","article-title":"Newborn screening for spinal muscular atrophy in Australia: a non-randomised cohort study","volume":"7","author":"Kariyawasam","year":"2023","journal-title":"Lancet Child Adolesc. Health"},{"key":"10.1016\/j.ymthe.2024.06.020_bib28","doi-asserted-by":"crossref","first-page":"101","DOI":"10.3233\/JND-200551","article-title":"Real-world data from nusinersen treatment for patients with later-onset spinal muscular atrophy: A single center experience","volume":"8","author":"Mendon\u00e7a","year":"2021","journal-title":"J.\u00a0Neuromuscul. Dis."},{"key":"10.1016\/j.ymthe.2024.06.020_bib29","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1002\/acn3.51276","article-title":"Type I SMA \u201cnew natural history\u201d: long-term data in nusinersen-treated patients","volume":"8","author":"Pane","year":"2021","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"10.1016\/j.ymthe.2024.06.020_bib30","first-page":"1","article-title":"Safety and effectiveness of nusinersen, a treatment for spinal muscular atrophy, in 524 patients: results from an interim analysis of post-marketing surveillance in Japan","volume":"7","author":"Tachibana","year":"2023","journal-title":"Int. J. Neurosci."},{"key":"10.1016\/j.ymthe.2024.06.020_bib31","article-title":"Long-term efficacy and safety of nusinersen in adults with 5q spinal muscular atrophy: a prospective European multinational observational study","volume":"39","author":"Gunther","year":"2024","journal-title":"Lancet Reg. Health Eur."},{"key":"10.1016\/j.ymthe.2024.06.020_bib32","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1093\/brain\/awac252","article-title":"Effect of nusinersen on motor, respiratory and bulbar function in early-onset spinal muscular atrophy","volume":"146","author":"Pechmann","year":"2023","journal-title":"Brain."},{"key":"10.1016\/j.ymthe.2024.06.020_bib33","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1186\/s13023-023-02769-4","article-title":"Long-term nusinersen treatment across a wide spectrum of spinal muscular atrophy severity: a real-world experience","volume":"18","author":"\u0141usakowska","year":"2023","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.ymthe.2024.06.020_bib34","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1212\/CPJ.0000000000000718","article-title":"A multidisciplinary approach to dosing nusinersen for spinal muscular atrophy","volume":"9","author":"Zingariello","year":"2019","journal-title":"Neurol. Clin. Prac"},{"key":"10.1016\/j.ymthe.2024.06.020_bib35","author":"Rabinowitz"},{"key":"10.1016\/j.ymthe.2024.06.020_bib36","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1001\/jamapediatrics.2017.4409","article-title":"Ethical Challenges Confronted When Providing Nusinersen Treatment for Spinal Muscular Atrophy","volume":"172","author":"Burgart","year":"2018","journal-title":"JAMA Pediatr."},{"key":"10.1016\/j.ymthe.2024.06.020_bib37","doi-asserted-by":"crossref","first-page":"3406","DOI":"10.1038\/s41598-020-60240-x","article-title":"Radiation dose reduction for CT-guided intrathecal nusinersen administration in adult patients with spinal muscular atrophy","volume":"10","author":"Cordts","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ymthe.2024.06.020_bib38","doi-asserted-by":"crossref","first-page":"e620","DOI":"10.1212\/WNL.0000000000006006","article-title":"Cervical puncture to deliver nusinersen in patients with spinal muscular atrophy","volume":"91","author":"Veerapandiyan","year":"2018","journal-title":"Neurology"},{"key":"10.1016\/j.ymthe.2024.06.020_bib39","doi-asserted-by":"crossref","first-page":"e4","DOI":"10.1002\/mus.26082","article-title":"Transforaminal lumbar puncture for intrathecal nusinersen administration","volume":"58","author":"Geraci","year":"2018","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.ymthe.2024.06.020_bib40","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1097\/CND.0000000000000333","article-title":"Delivery of nusinersen through an Ommaya reservoir in spinal muscular atrophy","volume":"22","author":"Iannaccone","year":"2021","journal-title":"J.\u00a0Clin. Neuromuscul. Dis."},{"key":"10.1016\/j.ymthe.2024.06.020_bib41","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1124\/dmd.121.000418","article-title":"Adverse Drug Reactions and Toxicity of the Food and Drug Administration-Approved Antisense Oligonucleotide Drugs","volume":"50","author":"Alhamadani","year":"2022","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.ymthe.2024.06.020_bib42","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1002\/mus.27217","article-title":"Laboratory monitoring of nusinersen safety","volume":"63","author":"Goedeker","year":"2021","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.ymthe.2024.06.020_bib43","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1007\/s40263-019-00656-w","article-title":"An integrated safety analysis of infants and children with symptomatic spinal muscular atrophy (SMA) treated with nusinersen in seven clinical trials","volume":"33","author":"Darras","year":"2019","journal-title":"CNS Drugs"},{"key":"10.1016\/j.ymthe.2024.06.020_bib44","doi-asserted-by":"crossref","first-page":"e79","DOI":"10.1002\/mus.27042","article-title":"Possible recurrent aseptic meningitis associated with nusinersen therapy","volume":"62","author":"Moshe-Lilie","year":"2020","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.ymthe.2024.06.020_bib45","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/s12883-024-03543-0","article-title":"Spinal adhesive arachnoiditis in an adult patient with spinal muscular atrophy type 3 treated with intrathecal therapy","volume":"24","author":"Ubysz","year":"2024","journal-title":"BMC Neurol."},{"key":"10.1016\/j.ymthe.2024.06.020_bib46","unstructured":"Nusinersen [package insert]: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/209531s005lbl.pdf."},{"key":"10.1016\/j.ymthe.2024.06.020_bib47","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1186\/s13023-021-01822-4","article-title":"The incidence of hydrocephalus among patients with and without spinal muscular atrophy (SMA): Results from a US electronic health records study","volume":"16","author":"Viscidi","year":"2021","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.ymthe.2024.06.020_bib48","first-page":"719","article-title":"Symptomatic intracranial hypertension in an adult patient\u00a0with spinal muscular atrophy and arachnoid cysts receiving nusinersen","volume":"10","author":"Machetanz","year":"2023","journal-title":"J.\u00a0Neuromusc Dis."},{"key":"10.1016\/j.ymthe.2024.06.020_bib49","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1007\/s40261-023-01320-4","article-title":"Safety concerns with nusinersen, risdiplam, and onasemnogene abeparvovec in spinal muscular atrophy: A real-world pharmacovigilance study","volume":"43","author":"Zhuang","year":"2023","journal-title":"Clin. Drug Investig."},{"key":"10.1016\/j.ymthe.2024.06.020_bib50","doi-asserted-by":"crossref","first-page":"367","DOI":"10.3390\/brainsci11030367","article-title":"Nusinersen wearing-off in adult 5q-spinal muscular atrophy patients","volume":"11","author":"Osmanovic","year":"2021","journal-title":"Brain Sci."},{"key":"10.1016\/j.ymthe.2024.06.020_bib51","doi-asserted-by":"crossref","first-page":"813","DOI":"10.3233\/JND-221667","article-title":"DEVOTE study exploring higher dose of nusinersen in spinal muscular atrophy: Study design and part A results","volume":"10","author":"Finkel","year":"2023","journal-title":"J.\u00a0Neuromuscul. Dis."},{"key":"10.1016\/j.ymthe.2024.06.020_bib52","doi-asserted-by":"crossref","first-page":"5809","DOI":"10.1007\/s12325-021-01938-w","article-title":"Nusinersen for spinal muscular atrophy in the United States: Findings from a retrospective claims database analysis","volume":"38","author":"Gauthier-Loiselle","year":"2021","journal-title":"Adv. Ther."},{"key":"10.1016\/j.ymthe.2024.06.020_bib53","doi-asserted-by":"crossref","first-page":"4589","DOI":"10.1007\/s12325-023-02621-y","article-title":"Health care resource utilization and costs for patients with Spinal Muscular Atrophy: Findings from a retrospective US claims database analysis","volume":"40","author":"Toro","year":"2023","journal-title":"Adv. Ther."},{"key":"10.1016\/j.ymthe.2024.06.020_bib54","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1007\/s12325-022-02414-9","article-title":"Examining real-world adherence to nusinersen for the treatment of spinal muscular atrophy using two large US data sources","volume":"40","author":"Youn","year":"2023","journal-title":"Adv. Ther."},{"key":"10.1016\/j.ymthe.2024.06.020_bib55","doi-asserted-by":"crossref","first-page":"e413","DOI":"10.1212\/WNL.0000000000009914","article-title":"Nusinersen in adult patients with spinal muscular atrophy: Observations from a single center","volume":"95","author":"Moshe-Lilie","year":"2020","journal-title":"Neurology"},{"key":"10.1016\/j.ymthe.2024.06.020_bib56","doi-asserted-by":"crossref","first-page":"e317","DOI":"10.1212\/CPJ.0000000000001033","article-title":"Nusinersen treatment in adults with spinal muscular atrophy","volume":"11","author":"Duong","year":"2021","journal-title":"Neurol. Clin. Pract."},{"key":"10.1016\/j.ymthe.2024.06.020_bib57","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1002\/mus.27116","article-title":"Early experiences of nusinersen for the treatment of spinal muscular atrophy: Results from a large survey of patients and caregivers","volume":"63","author":"Chen","year":"2021","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.ymthe.2024.06.020_bib58","doi-asserted-by":"crossref","first-page":"6501","DOI":"10.1021\/acs.jmedchem.8b00741","article-title":"Discovery of risdiplam, a selective survival of motor neuron-2 (SMN2) gene splicing modifier for the treatment of spinal muscular atrophy (SMA)","volume":"61","author":"Ratni","year":"2018","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ymthe.2024.06.020_bib59","unstructured":"Risdiplam [package insert]: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/213535s003s005lbl.pdf."},{"key":"10.1016\/j.ymthe.2024.06.020_bib60","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1056\/NEJMoa2009965","article-title":"Risdiplam in type 1 spinal muscular atrophy","volume":"384","author":"Baranello","year":"2021","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2024.06.020_bib61","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S1474-4422(21)00367-7","article-title":"Safety and efficacy of once-daily risdiplam in type 2 and non-ambulant type 3 spinal muscular atrophy (SUNFISH part 2): a phase 3, double-blind, randomised, placebo-controlled trial","volume":"21","author":"Mercuri","year":"2022","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.ymthe.2024.06.020_bib62","doi-asserted-by":"crossref","first-page":"s88","DOI":"10.1016\/j.nmd.2022.07.194","article-title":"P.109 FIREFISH Parts 1 and 2: 36-month safety and efficacy of risdiplam in Type 1 spinal muscular atrophy (SMA)","volume":"32","author":"Servais","year":"2022","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.ymthe.2024.06.020_bib63","series-title":"Poster Presented at the American Academy of Neurology Annual Meeting 2023","article-title":"SUNFISH Parts 1 and 2: 4-year efficacy and safety data of risdiplam in types 2 and 3 spinal muscular atrophy (SMA)","author":"Servais","year":"2023"},{"key":"10.1016\/j.ymthe.2024.06.020_bib64","doi-asserted-by":"crossref","first-page":"4281","DOI":"10.1212\/WNL.96.15_supplement.4281","article-title":"RAINBOWFISH: A study of risdiplam in newborns with presymptomatic spinal muscular atrophy (SMA)","volume":"96","author":"Finkel","year":"2021","journal-title":"Neurology"},{"key":"10.1016\/j.ymthe.2024.06.020_bib65","doi-asserted-by":"crossref","first-page":"s87","DOI":"10.1016\/j.nmd.2023.07.094","article-title":"P212 RAINBOWFISH: Primary efficacy and safety data in risdiplam-treated infants with presymptomatic spinal muscular atrophy (SMA)","volume":"33","author":"Finkel","year":"2023","journal-title":"Neuromusc Dis."},{"key":"10.1016\/j.ymthe.2024.06.020_bib66","series-title":"Poster Presented at 2022 Virtual World Muscle Society (WMS) Conference; Halifax, Canada","article-title":"JEWELFISH: 24-month safety, pharmacodynamic and exploratory efficacy data in non-treatment-na\u00efve patients with SMA receiving treatment with risdiplam","author":"Chiriboga","year":"2022"},{"key":"10.1016\/j.ymthe.2024.06.020_bib67","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1007\/s40120-023-00444-1","article-title":"Risdiplam in patients previously treated with other therapies for spinal muscular atrophy: An interim analysis from the JEWELFISH Study","volume":"12","author":"Chiriboga","year":"2023","journal-title":"Neurol. Ther."},{"key":"10.1016\/j.ymthe.2024.06.020_bib68","doi-asserted-by":"crossref","first-page":"361","DOI":"10.3233\/JND-230162","article-title":"Risdiplam in spinal muscular atrophy: Safety profile and use through the early access to medicine scheme for the paediatric cohort in Great Britain","volume":"11","author":"Cornell","year":"2024","journal-title":"J.\u00a0Neuromuscul. Dis."},{"key":"10.1016\/j.ymthe.2024.06.020_bib69","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1186\/s13023-022-02420-8","article-title":"Short-term safety results from compassionate use of risdiplam in patients with spinal muscular atrophy in Germany","volume":"17","author":"Hahn","year":"2022","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.ymthe.2024.06.020_bib70","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1002\/acn3.51560","article-title":"An expanded access program of risdiplam for patients with Type 1 or 2 spinal muscular atrophy","volume":"9","author":"Kwon","year":"2022","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"10.1016\/j.ymthe.2024.06.020_bib71","doi-asserted-by":"crossref","first-page":"75","DOI":"10.3233\/JND-230197","article-title":"Risdiplam Real World\u00a0Data - Looking Beyond Motor Neurons and Motor Function Measures","volume":"11","author":"Sitas","year":"2024","journal-title":"J.\u00a0Neuromuscul. Dis."},{"key":"10.1016\/j.ymthe.2024.06.020_bib72","first-page":"2649","article-title":"Risdiplam improves subjective swallowing quality in non-ambulatory adult patients with 5q-spinal muscular atrophy despite advanced motor impairment","volume":"271","author":"Brakemeier","year":"2024","journal-title":"J.\u00a0Neurol."},{"key":"10.1016\/j.ymthe.2024.06.020_bib73","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1002\/mus.27755","article-title":"Risdiplam for the treatment of adults with spinal muscular atrophy: Experience of the Northern Ireland neuromuscular service","volume":"67","author":"McCluskey","year":"2023","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.ymthe.2024.06.020_bib74","doi-asserted-by":"crossref","DOI":"10.1016\/j.nmd.2022.07.087","article-title":"P.51 Real-world experience after one year treating SMA children with risdiplam","volume":"32","author":"de la Banda","year":"2022","journal-title":"Neuromusc Dis."},{"key":"10.1016\/j.ymthe.2024.06.020_bib75","series-title":"Poster at the Muscular Dystrophy Association (MDA) Clinical and Scientific Conference, Orlando, FL, USA; March 3\u20136, 2024","article-title":"Real-world use of risdiplam for the treatment of spinal muscular atrophy (SMA) in infants under 2\u00a0months of age in the US","author":"Shapouri","year":"2024"},{"key":"10.1016\/j.ymthe.2024.06.020_bib76","unstructured":"https:\/\/www.evrysdi.com\/taking-evrysdi\/taking-evrysdi.html."},{"key":"10.1016\/j.ymthe.2024.06.020_bib77","doi-asserted-by":"crossref","first-page":"s92","DOI":"10.1016\/j.nmd.2023.07.112","article-title":"P230 Safety update: Risdiplam clinical trial program for spinal muscular atrophy (SMA)","volume":"33","author":"Baranello","year":"2023","journal-title":"Neuromusc Dis."},{"key":"10.1016\/j.ymthe.2024.06.020_bib78","first-page":"1","article-title":"Consensus from the Brazilian Academy of Neurology for the diagnosis, genetic counseling, and use of disease-modifying therapies in 5q spinal muscular atrophy","volume":"82","author":"Zanoteli","year":"2024","journal-title":"Arq. Neuropsiquiatr."},{"key":"10.1016\/j.ymthe.2024.06.020_bib79","doi-asserted-by":"crossref","first-page":"5913","DOI":"10.3390\/ijms22115913","article-title":"Metabolic dysfunction in spinal muscular atrophy","volume":"22","author":"Deguise","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ymthe.2024.06.020_bib80","doi-asserted-by":"crossref","DOI":"10.1016\/j.reprotox.2023.108360","article-title":"Reproductive findings in male animals exposed to selective survival of motor neuron 2 (SMN2) gene splicing-modifying agents","volume":"118","author":"Mueller","year":"2023","journal-title":"Reprod. Toxicol."},{"key":"10.1016\/j.ymthe.2024.06.020_bib81","first-page":"s209","article-title":"Real world experience of risdiplam in newborns with spinal muscular atrophy (SMA): a multicenter, retrospective cohort study","volume":"33","author":"Goedeker","year":"2023","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.ymthe.2024.06.020_bib82","unstructured":"Onasemnogene abeparvovec [package insert]: https:\/\/www.fda.gov\/media\/126109\/download?attachment."},{"key":"10.1016\/j.ymthe.2024.06.020_bib83","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1706198","article-title":"Single-dose gene-replacement therapy for spinal muscular atrophy","volume":"377","author":"Mendell","year":"2017","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2024.06.020_bib84","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1172\/JCI41615","article-title":"CNS-targeted gene therapy improves survival and motor function in a mouse model of spinal muscular atrophy","volume":"120","author":"Passini","year":"2010","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.ymthe.2024.06.020_bib85","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1172\/JCI22922","article-title":"Lentivector-mediated SMN replacement in a mouse model of spinal muscular atrophy","volume":"114","author":"Azzous","year":"2004","journal-title":"J.\u00a0Clin. Invest"},{"key":"10.1016\/j.ymthe.2024.06.020_bib86","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1038\/mt.2009.71","article-title":"Intravenous administration of self-complementary AAV9 enables transgene delivery to adult motor neurons","volume":"17","author":"Duque","year":"2009","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2024.06.020_bib87","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/nbt.1515","article-title":"Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes","volume":"27","author":"Foust","year":"2009","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ymthe.2024.06.020_bib88","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1093\/hmg\/ddq514","article-title":"Intravenous scAAV9 delivery of a codon-optimized SMN1 sequence rescues SMA mice","volume":"20","author":"Dominguez","year":"2011","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.ymthe.2024.06.020_bib89","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1001\/jamaneurol.2021.1272","article-title":"Five-year extension results of the phase 1 START trial of onasemnogene abeparvovec in spinal muscular atrophy","volume":"78","author":"Mendell","year":"2021","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.ymthe.2024.06.020_bib90","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1038\/s41591-021-01483-7","article-title":"Biodistribution of onasemnogene abeparvovec DNA, mRNA and SMN protein in human tissue","volume":"27","author":"Thomsen","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2024.06.020_bib91","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/S1474-4422(21)00001-6","article-title":"Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy in patients with two copies of SMN2 (STR1VE): an open-label, single-arm, multicentre, phase 3 trial","volume":"20","author":"Day","year":"2021","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.ymthe.2024.06.020_bib92","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/S1474-4422(21)00251-9","article-title":"Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy type 1 (STR1VE-EU): an open-label, single-arm, multicentre, phase 3 trial","volume":"20","author":"Mercuri","year":"2021","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.ymthe.2024.06.020_bib93","doi-asserted-by":"crossref","first-page":"2674","DOI":"10.1093\/hmg\/ddaa146","article-title":"Pre-natal manifestation of systemic developmental abnormalities in spinal muscular atrophy","volume":"29","author":"Motyl","year":"2020","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.ymthe.2024.06.020_bib94","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1038\/s41591-022-01867-3","article-title":"Onasemnogene abeparvovec for presymptomatic infants with three copies of SMN2 at risk for spinal muscular atrophy: The Phase III SPR1NT trial","volume":"28","author":"Strauss","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2024.06.020_bib95","doi-asserted-by":"crossref","first-page":"145","DOI":"10.3233\/JND-190451","article-title":"RESTORE: A prospective multinational registry of patients with genetically confirmed Spinal Muscular Atrophy - Rationale and study design","volume":"7","author":"Finkel","year":"2020","journal-title":"J.\u00a0Neuromuscul. Dis."},{"key":"10.1016\/j.ymthe.2024.06.020_bib96","doi-asserted-by":"crossref","first-page":"425","DOI":"10.3233\/JND-230122","article-title":"Real-world outcomes in patients with spinal muscular atrophy treated with onasemnogene abeparvovec monotherapy: Findings from the RESTORE registry","volume":"11","author":"Servais","year":"2024","journal-title":"J.\u00a0Neuromuscul. Dis."},{"key":"10.1016\/j.ymthe.2024.06.020_bib97","series-title":"Poster Presented at OttawaNMD Conference, September 2023","article-title":"Outcomes of early treated infants with spinal muscular atrophy: A multicenter retrospective cohort study","author":"Goedeker","year":"2023"},{"key":"10.1016\/j.ymthe.2024.06.020_bib98","series-title":"Presented at the 2023 Muscular Dystrophy Association Clinical and Scientific Conference; Dallas, TX, USA","article-title":"Long-term follow-up of onasemnogene abeparvovec gene therapy in symptomatic patients with spinal muscular atrophy type 1","author":"Mendell","year":"2023"},{"key":"10.1016\/j.ymthe.2024.06.020_bib99","series-title":"Proceedings of the 2023 MDA Clinical\u00a0& Scientific Conference; Dallas, TX, USA","article-title":"Intravenous and intrathecal onasemnogene abeparvovec gene therapy in asymptomatic and presymptomatic spinal muscular atrophy: Long-term follow-up study","author":"Connolly","year":"2023"},{"key":"10.1016\/j.ymthe.2024.06.020_bib100","doi-asserted-by":"crossref","first-page":"389","DOI":"10.3233\/JND-221560","article-title":"Intrathecal onasemnogene abeparvovec for sitting, nonambulatory patients with spinal muscular atrophy: Phase I ascending-dose study (STRONG)","volume":"10","author":"Finkel","year":"2023","journal-title":"J.\u00a0Neuromuscul. Dis."},{"key":"10.1016\/j.ymthe.2024.06.020_bib101","doi-asserted-by":"crossref","DOI":"10.1016\/j.nmd.2023.07.093","article-title":"P211 Intravenous and intrathecal onasemnogene abeparvovec gene therapy in symptomatic and presymptomatic spinal muscular atrophy (SMA): long-term follow-up study","volume":"33","author":"Darras","year":"2023","journal-title":"Neuromusc Dis."},{"key":"10.1016\/j.ymthe.2024.06.020_bib102","article-title":"Efficacy and safety of onasemnogene abeparvovec in children with spinal muscular atrophy type 1: real-world evidence from 6 infusion centres in the United Kingdom","volume":"37","author":"Gowda","year":"2024","journal-title":"Lancet Reg. Health Eur."},{"key":"10.1016\/j.ymthe.2024.06.020_bib103","first-page":"437","article-title":"Onasemnogene Abeparvovec (AVXS-101) for the Treatment of Spinal Muscular Atrophy","volume":"26","author":"Naveed","year":"2021","journal-title":"J.\u00a0Pediatr. Pharmacol. Ther."},{"key":"10.1016\/j.ymthe.2024.06.020_bib104","series-title":"Presented at the 2024 Muscular Dystrophy Association (MDA) Clinical\u00a0& Scientific Conference, March 2024; Orlando, FL, USA","article-title":"Safety and efficacy of intravenous onasemnogene abeparvovec in pediatric patients with spinal muscular atrophy: Findings from the phase 3b SMART Study","author":"Mcmillan","year":"2024"},{"key":"10.1016\/j.ymthe.2024.06.020_bib105","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1111\/jpc.16340","article-title":"Safety and efficacy of gene therapy with onasemnogene abeparvovec in the treatment of spinal muscular atrophy: A systematic review and meta-analysis","volume":"59","author":"Yang","year":"2023","journal-title":"J.\u00a0Paediatr. Child Health"},{"key":"10.1016\/j.ymthe.2024.06.020_bib106","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2020-0729","article-title":"Gene therapy for Spinal Muscular Atrophy: Safety and early outcomes","volume":"146","author":"Waldrop","year":"2020","journal-title":"Pediatrics"},{"key":"10.1016\/j.ymthe.2024.06.020_bib107","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.pediatrneurol.2023.04.007","article-title":"Real-life outcome after gene replacement therapy for Spinal Muscular Atrophy: A multicenter experience","volume":"144","author":"Tokatly Latzer","year":"2023","journal-title":"Pediatr. Neurol."},{"key":"10.1016\/j.ymthe.2024.06.020_bib108","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1002\/acn3.51519","article-title":"Onasemnogene abeparvovec in spinal muscular atrophy: an Australian experience of safety and efficacy","volume":"9","author":"D'Silva","year":"2022","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"10.1016\/j.ymthe.2024.06.020_bib109","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1002\/ppul.26285","article-title":"A breakthrough effect of gene replacement therapy on respiratory outcomes in children with spinal muscular atrophy","volume":"58","author":"Al Naimi","year":"2023","journal-title":"Pediatr. Pulmonol."},{"key":"10.1016\/j.ymthe.2024.06.020_bib110","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1159\/000007926","article-title":"Analysis of creatine kinase activity in 504 patients with proximal spinal muscular atrophy types I-III from the point of view of progression and severity","volume":"39","author":"Rudnik-Sch\u00f6neborn","year":"1998","journal-title":"Eur. Neurol."},{"key":"10.1016\/j.ymthe.2024.06.020_bib111","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.omtm.2022.02.011","article-title":"Testing preexisting antibodies prior to AAV gene transfer therapy: rationale, lessons and future considerations","volume":"25","author":"Mendell","year":"2022","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.ymthe.2024.06.020_bib112","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1002\/mus.27363","article-title":"Expert recommendations and clinical considerations in the use of onasemnogene abeparvovec gene therapy for spinal muscular atrophy","volume":"64","author":"Kichula","year":"2021","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.ymthe.2024.06.020_bib113","doi-asserted-by":"crossref","first-page":"s72","DOI":"10.1016\/j.nmd.2023.07.037","article-title":"P56 Preliminary study of anti-AAVrh74 seroprevalence following gene transfer","volume":"33","author":"D'Ambrosio","year":"2023","journal-title":"Neuromusc Dis."},{"key":"10.1016\/j.ymthe.2024.06.020_bib114","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/j.jhep.2020.11.001","article-title":"Hepatotoxicity following administration of onasemnogene abeparvovec (AVXS-101) for the treatment of spinal muscular atrophy","volume":"74","author":"Chand","year":"2021","journal-title":"J.\u00a0Hepatol."},{"key":"10.1016\/j.ymthe.2024.06.020_bib115","doi-asserted-by":"crossref","first-page":"4266","DOI":"10.1182\/bloodadvances.2021006419","article-title":"Fatal thrombotic microangiopathy case following adeno-associated viral SMN gene therapy","volume":"6","author":"Guillou","year":"2022","journal-title":"Blood Adv."},{"key":"10.1016\/j.ymthe.2024.06.020_bib116","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.jpeds.2020.11.054","article-title":"Thrombotic microangiopathy following onasemnogene abeparvovec for spinal muscular atrophy: A case series","volume":"231","author":"Chand","year":"2021","journal-title":"J.\u00a0Pediatr."},{"key":"10.1016\/j.ymthe.2024.06.020_bib117","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1089\/hum.2021.255","article-title":"Single-dose intrathecal dorsal root ganglia toxicity of onasemnogene abeparvovec in cynomolgus monkeys","volume":"33","author":"Tukov","year":"2022","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2024.06.020_bib118","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1089\/hum.2018.015","article-title":"Severe toxicity in nonhuman primates and piglets following high-dose intravenous administration of an adeno-associated virus vector expressing human SMN","volume":"29","author":"Hinderer","year":"2018","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2024.06.020_bib119","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1038\/s41593-021-00827-3","article-title":"Gain of toxic function by long-term AAV9-mediated SMN overexpression in the sensorimotor circuit","volume":"24","author":"Van Alstyne","year":"2021","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.ymthe.2024.06.020_bib120","unstructured":"https:\/\/clinicaltrials.gov\/study\/NCT05089656."},{"key":"10.1016\/j.ymthe.2024.06.020_bib121","doi-asserted-by":"crossref","first-page":"2991","DOI":"10.1016\/j.ymthe.2023.08.013","article-title":"Epithelioid neoplasm of the spinal cord in a child with spinal muscular atrophy treated with onasemnogene abeparvovec","volume":"31","author":"Retson","year":"2023","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2024.06.020_bib122","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1002\/mus.27358","article-title":"Selecting disease-modifying medications in 5q spinal muscular atrophy","volume":"64","author":"Cartwright","year":"2021","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.ymthe.2024.06.020_bib123","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1002\/mus.28015","article-title":"A case series evaluating patient perceptions after switching from nusinersen to risdiplam for spinal muscular atrophy","volume":"69","author":"Powell","year":"2024","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.ymthe.2024.06.020_bib124","doi-asserted-by":"crossref","first-page":"244","DOI":"10.3390\/jpm14030244","article-title":"Switching from nusinersen to risdiplam: A Croatian real-world experience on effectiveness and safety","volume":"14","author":"Belan\u010di\u0107","year":"2024","journal-title":"J.\u00a0Pers. Med."},{"key":"10.1016\/j.ymthe.2024.06.020_bib125","doi-asserted-by":"crossref","first-page":"347","DOI":"10.2217\/cer-2021-0216","article-title":"How does risdiplam compare with other treatments for Types 1-3 spinal muscular atrophy: a systematic literature review and indirect treatment comparison","volume":"11","author":"Ribero","year":"2022","journal-title":"J.\u00a0Comp. Eff. Res."},{"key":"10.1016\/j.ymthe.2024.06.020_bib126","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1080\/03007995.2021.1947216","article-title":"Matching-adjusted indirect treatment comparison of onasemnogene abeparvovec and nusinersen for the treatment of symptomatic patients with spinal muscular atrophy type 1","volume":"37","author":"Bischof","year":"2021","journal-title":"Curr. Med. Res. Opin."},{"key":"10.1016\/j.ymthe.2024.06.020_bib127","doi-asserted-by":"crossref","first-page":"s164","DOI":"10.1016\/j.nmd.2023.07.385","article-title":"P08 Long-term comparative efficacy and safety of risdiplam versus nusinersen in children with Type 1 spinal muscular atrophy (SMA)","volume":"33","author":"Sajeev","year":"2023","journal-title":"Neuromusc Dis."},{"key":"10.1016\/j.ymthe.2024.06.020_bib128","doi-asserted-by":"crossref","first-page":"2985","DOI":"10.1007\/s12325-023-02520-2","article-title":"A critical appraisal of matching-adjusted indirect comparisons in spinal muscular atrophy","volume":"40","author":"Jiang","year":"2023","journal-title":"Adv. Ther."},{"key":"10.1016\/j.ymthe.2024.06.020_bib129","doi-asserted-by":"crossref","first-page":"2481","DOI":"10.1002\/acn3.51126","article-title":"Nusinersen in type 0 spinal muscular atrophy: should we treat?","volume":"7","author":"Tiberi","year":"2020","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"10.1016\/j.ymthe.2024.06.020_bib130","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1002\/acn3.51459","article-title":"The need for evidence-based treatment decisions in spinal muscular atrophy type 0","volume":"8","author":"Erbas","year":"2021","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"10.1016\/j.ymthe.2024.06.020_bib131","series-title":"Poster at the MDA Clinical and Scientific Conference","article-title":"Real-world outcomes following Onasemnogene abeparvovec in patients with SMA and one SMN2 gene copy: Findings from the RESTORE registry","author":"Finkel","year":"2024"},{"key":"10.1016\/j.ymthe.2024.06.020_bib132","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.nmd.2018.01.003","article-title":"Correlation between SMA type and SMN2 copy number revisited: An analysis of 625 unrelated Spanish patients and a compilation of 2834 reported cases","volume":"28","author":"Calucho","year":"2018","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.ymthe.2024.06.020_bib133","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1002\/ana.26788","article-title":"Clinical phenotype of pediatric and adult patients with spinal muscular atrophy with four SMN2 Copies: Are they really all stable?","volume":"94","author":"Ricci","year":"2023","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.ymthe.2024.06.020_bib134","doi-asserted-by":"crossref","first-page":"145","DOI":"10.3233\/JND-180304","article-title":"Treatment algorithm for infants diagnosed with spinal muscular atrophy through newborn screening","volume":"5","author":"Glascock","year":"2018","journal-title":"J.\u00a0Neuromuscul. Dis."},{"key":"10.1016\/j.ymthe.2024.06.020_bib135","doi-asserted-by":"crossref","first-page":"97","DOI":"10.3233\/JND-190468","article-title":"Revised recommendations for the treatment of infants diagnosed with spinal muscular atrophy via newborn screening who have 4 copies of SMN2","volume":"7","author":"Glascock","year":"2020","journal-title":"J.\u00a0Neuromuscul. Dis."},{"key":"10.1016\/j.ymthe.2024.06.020_bib136","doi-asserted-by":"crossref","first-page":"109","DOI":"10.3233\/JND-200475","article-title":"Infants diagnosed with spinal muscular atrophy and 4 SMN2 copies through newborn screening - opportunity or burden?","volume":"7","author":"M\u00fcller-Felber","year":"2020","journal-title":"J.\u00a0Neuromuscul. Dis."},{"key":"10.1016\/j.ymthe.2024.06.020_bib137","doi-asserted-by":"crossref","first-page":"597","DOI":"10.3233\/JND-221510","article-title":"Newborn screening for SMA - Can a wait-and-see strategy be responsibly justified in patients with four SMN2 copies?","volume":"9","author":"Blaschek","year":"2022","journal-title":"J.\u00a0Neuromuscul. Dis."},{"key":"10.1016\/j.ymthe.2024.06.020_bib138","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1002\/ana.24332","article-title":"A large animal model of spinal muscular atrophy and correction of phenotype","volume":"77","author":"Duque","year":"2015","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.ymthe.2024.06.020_bib139","series-title":"Presented at 2023 Cure SMA Research\u00a0& Clinical Care; Orlando, FL","article-title":"Interim results from the ongoing RESPOND study evaluating nusinersen in children with spinal muscular atrophy previously treated with onasemnogene abeparvovec","author":"Proud","year":"2023"},{"key":"10.1016\/j.ymthe.2024.06.020_bib140","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1002\/acn3.51889","article-title":"Combination disease-modifying treatment in spinal muscular atrophy: A proposed classification","volume":"10","author":"Proud","year":"2023","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"10.1016\/j.ymthe.2024.06.020_bib141","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1002\/mus.27375","article-title":"Combination therapy with onasemnogene and risdiplam in spinal muscular atrophy type 1","volume":"64","author":"Oechsel","year":"2021","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.ymthe.2024.06.020_bib142","first-page":"82","article-title":"Sequential treatment with nusinersen, Zolgensma\u00ae and risdiplam in a paediatric patient with spinal muscular atrophytype 1: a case report","volume":"42","author":"Bitetti","year":"2023","journal-title":"Acta Myol."},{"key":"10.1016\/j.ymthe.2024.06.020_bib143","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1002\/mus.27034","article-title":"Combination molecular therapies for type 1 spinal muscular atrophy","volume":"62","author":"Harada","year":"2020","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.ymthe.2024.06.020_bib144","doi-asserted-by":"crossref","first-page":"365","DOI":"10.3233\/JND-221551","article-title":"The Muscular Dystrophy Association's neuroMuscular ObserVational Research Data Hub (MOVR): Design, methods, and initial observations","volume":"10","author":"Kilroy","year":"2023","journal-title":"J.\u00a0Neuromuscul. Dis."},{"key":"10.1016\/j.ymthe.2024.06.020_bib145","series-title":"Poster Presented at American Academy of Neurology Annual Conference 2023","article-title":"Baseline characteristics and interim safety in RESPOND: A phase 4 study in children with spinal muscular atrophy (SMA) treated With Nusinersen after Onasemnogene Abeparvovec","author":"Kuntz","year":"2023"},{"key":"10.1016\/j.ymthe.2024.06.020_bib146","unstructured":"https:\/\/www.clinicaltrials.gov\/study\/NCT05861999?term=hinalea&rank=1."},{"key":"10.1016\/j.ymthe.2024.06.020_bib147","unstructured":"https:\/\/clinicaltrials.gov\/study\/NCT05861986?term=hinalea&rank=2."},{"key":"10.1016\/j.ymthe.2024.06.020_bib148","doi-asserted-by":"crossref","first-page":"5540","DOI":"10.3390\/jcm10235540","article-title":"Combination therapy with nusinersen and onasemnogene abeparvovec-xioi in spinal muscular atrophy type I","volume":"10","author":"Mirea","year":"2021","journal-title":"J.\u00a0Clin. Med."},{"key":"10.1016\/j.ymthe.2024.06.020_bib149","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S2352-4642(21)00287-X","article-title":"Gene replacement therapy with onasemnogene abeparvovec in children with spinal muscular atrophy aged 24\u00a0months or younger and bodyweight up to 15\u00a0kg: an observational cohort study","volume":"6","author":"Wei\u00df","year":"2022","journal-title":"Lancet Child Adolesc. Health"},{"key":"10.1016\/j.ymthe.2024.06.020_bib150","unstructured":"https:\/\/www.curesma.org\/wp-content\/uploads\/2024\/01\/NBS_Maps_Screening_States_2024.pdf."},{"key":"10.1016\/j.ymthe.2024.06.020_bib151","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.3390\/genes14071377","article-title":"Spinal muscular atrophy treatment in patients identified by newborn screening - a systematic review","volume":"14","author":"Aragon-Gawinska","year":"2023","journal-title":"Genes (Basel)"},{"key":"10.1016\/j.ymthe.2024.06.020_bib152","doi-asserted-by":"crossref","first-page":"e41","DOI":"10.1097\/AOG.0000000000001952","article-title":"Committee Opinion No. 691. Carrier screening for genetic conditions","volume":"129","year":"2017","journal-title":"Obstet. Gynecol."},{"key":"10.1016\/j.ymthe.2024.06.020_bib153","doi-asserted-by":"crossref","first-page":"e520","DOI":"10.1542\/neo.23-7-e520","article-title":"Spinal muscular atrophy type 1: Fetal diagnosis, prenatal coordination, and postnatal management in the era of novel therapies","volume":"23","author":"Chitkara","year":"2022","journal-title":"Neoreviews"},{"key":"10.1016\/j.ymthe.2024.06.020_bib154","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1002\/pd.6228","article-title":"Investigating attitudes toward prenatal diagnosis and fetal therapy for spinal muscular atrophy","volume":"42","author":"Schwab","year":"2022","journal-title":"Prenat. Diagn."},{"key":"10.1016\/j.ymthe.2024.06.020_bib155","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1097\/GRF.0000000000000654","article-title":"Spinal muscular atrophy: A potential target for in utero therapy","volume":"64","author":"Baptiste","year":"2021","journal-title":"Clin. Obstet. Gynecol."},{"key":"10.1016\/j.ymthe.2024.06.020_bib156","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1016\/j.ymthe.2019.08.017","article-title":"Fetal gene therapy using a single injection of recombinant AAV9 rescued SMA phenotype in mice","volume":"27","author":"Rashnonejad","year":"2019","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2024.06.020_bib157","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1002\/mus.27261","article-title":"Time is muscle: A recommendation for early treatment for preterm infants with spinal muscular atrophy","volume":"64","author":"Lee","year":"2021","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.ymthe.2024.06.020_bib158","series-title":"Poster presentation American Academy of Neurology Annual Meeting 2023","article-title":"The use of onasemnogene abeparvovec at 33\u00a0weeks\u2019 gestation in spinal muscular atrophy with one copy of\u00a0SMN2","author":"Ajjarapu","year":"2023"},{"key":"10.1016\/j.ymthe.2024.06.020_bib159","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2023.1230889","article-title":"Case report: A case of spinal muscular atrophy in a preterm infant: risks and benefits of treatment","volume":"14","author":"Nigro","year":"2023","journal-title":"Front. Neurol."},{"key":"10.1016\/j.ymthe.2024.06.020_bib160","doi-asserted-by":"crossref","DOI":"10.3389\/fncel.2022.916065","article-title":"Commentary: Current status of gene therapy for spinal muscular atrophy","volume":"16","author":"Rossoll","year":"2022","journal-title":"Front. Cell. Neurosci."},{"key":"10.1016\/j.ymthe.2024.06.020_bib161","first-page":"S1","article-title":"Biodistributional study of novel AAV-F capsid vs AAV9 after neonatal intravenous delivery. Presentation at ASGCT\u2019s 26th Annual Meeting, May 16-May 20, 2023","volume":"31","author":"Keegan","year":"2023","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2024.06.020_bib162","first-page":"S1","article-title":"Low-dose intracerebroventricular delivery of a second-generation AAV gene therapy for spinal muscular atrophy achieves efficient and toxicity-free motor function rescue in mice. Presentation at ASGCT\u2019s 26th Annual Meeting, May 16-May 20, 2023","volume":"31","author":"Chen","year":"2023","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2024.06.020_bib163","article-title":"Engineered virus-like particles enable high efficiency of base editing in hiPSC-derived motor neurons. Presentation at ASGCT\u2019s 26th Annual Meeting, May 16-May 20, 2023","volume":"31","author":"Zhou","year":"2023","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2024.06.020_bib164","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1136\/archdischild-2023-325762","article-title":"Understanding caregiver experiences with disease-modifying therapies for spinal muscular atrophy: a qualitative study","volume":"108","author":"Xiao","year":"2023","journal-title":"Arch. Dis. Child."},{"key":"10.1016\/j.ymthe.2024.06.020_bib165","doi-asserted-by":"crossref","DOI":"10.1212\/CPJ.0000000000200224","article-title":"Life-saving treatments for spinal muscular atrophy: Global access and availability","volume":"14","author":"Armengol","year":"2024","journal-title":"Neurol. Clin. Pract."},{"key":"10.1016\/j.ymthe.2024.06.020_bib166","first-page":"S1","article-title":"A study on health equity challenges, addressing social determinants of health to improve access to cell and gene therapies in US. Presentation at ASGCT\u2019s 26th Annual Meeting, May 16-May 20, 2023","volume":"31","author":"Rahul","year":"2023","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2024.06.020_bib167","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.pediatrneurol.2020.01.003","article-title":"Overturning the paradigm of spinal muscular atrophy as just a motor neuron disease","volume":"109","author":"Yeo","year":"2020","journal-title":"Pediatr. Neurol."}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001624004027?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001624004027?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,22]],"date-time":"2025-11-22T02:50:38Z","timestamp":1763779838000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525001624004027"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":167,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["S1525001624004027"],"URL":"https:\/\/doi.org\/10.1016\/j.ymthe.2024.06.020","relation":{},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical perspectives: Treating spinal muscular atrophy","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymthe.2024.06.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The American Society of Gene and Cell Therapy. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}